Evidence map›Paper›PMID 35835105›Full record

ArticleCell reports. Medicine2022

CD8

Oliver Van Oekelen, Samir Parekh

Open access · goldAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Oliver Van OekelenTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Mount Sinai Beth Israel, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Samir ParekhTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: samir.parekh@mssm.edu.
Icahn School of Medicine at Mount Sinai · US

Funding

THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ramon E Parsons · 2015 to 2026
$35.4M
Development of a multi-omic clinical decision platform to guide personalized therapyR01CA244899 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI PAREKH, SAMIR · 2020 to 2024
$2.8M
Targeting SOX11 in Mantle Cell LymphomaR01CA252222 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI PAREKH, SAMIR, WANG, MICHAEL · 2020 to 2024
$2.8M
NCI NIH HHS P30 CA196521NCI NIH HHS R01 CA244899NCI NIH HHS R01 CA252222
6 · The paper itself

Abstract

In a diverse cohort of cancer patients, Lyudovyk et al.

Indexed as

COVID-19NeoplasmsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesHumans

Identifiers

PMID35835105
PMCPMC9233996
OpenAlexW4283585275

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.